/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
We are a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. In October 2025, we announced plans to explore strategic alternatives focused on maximizing stockholder value after being unable to align with the U.S.
ROIC dropped from -42.15% to -45.45%, capital efficiency is deteriorating. Negative free cash flow of -$52M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$0.00
Net Income (TTM)
-$45M
▲ +33.1% YoY
Op. Margin
—
ROIC
-45.97%
▼ -3.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$42M
▲ +30.2% YoY
Op. Cash Flow (TTM)
-$42M
▲ +30.2% YoY
Net Debt
-$65M
Net Cash Position
Cash & Equiv.
$66M
Continue Research
SourceComputed from the 10-Q filed 11 May 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 12 May 2026. How this is calculated.
Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.